AU1961600A - Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt - Google Patents

Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt Download PDF

Info

Publication number
AU1961600A
AU1961600A AU19616/00A AU1961600A AU1961600A AU 1961600 A AU1961600 A AU 1961600A AU 19616/00 A AU19616/00 A AU 19616/00A AU 1961600 A AU1961600 A AU 1961600A AU 1961600 A AU1961600 A AU 1961600A
Authority
AU
Australia
Prior art keywords
weight
pharmaceutical preparation
per
powder
camomile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU19616/00A
Other versions
AU747416B2 (en
Inventor
Norbert Gschwend
Norbert A. Gschwend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1961600A publication Critical patent/AU1961600A/en
Application granted granted Critical
Publication of AU747416B2 publication Critical patent/AU747416B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

WO 00/43021 PCT/CH00/00027 PHARMACEUTICAL PREPARATION, , CONTAINING SULFUR, MUSTARD SEEDS AND A CUPRIC SALT, FOR TREATING RHEUMATIC SYNDROMES This invention relates to a pharmaceutical preparation offering significantly improved properties in the treatment of rheumatic syndromes, especially rheumatism, arthritis, sciatica and/or gout, a cutaneous form of administration of a pharmaceutical preparation, a foot powder, as well as a method for producing a pharmaceutical preparation and, respectively, a foot powder. Existing literature describes various active agents used in treating rheumatic and rheumatoid syndromes. For example, in a special supplement to "Zeitschrift for Arztliche Fortbildung" (journal for advanced medical training), vol. XIII, 15 Nov 1959, No. 150, pages 798 to 802, titled "the practical physician", H. Seliger states that it is especially colloidal sulfur that has proved effective in treating rheumatism, arthritis and sciatia, among others. Beneficial additives mentioned by him include camphor and camomile flowers. H. Seliger makes special reference to a pharmaceutical preparation marketed by the N. Gschwend company of Herisau which contains the three active ingredients mentioned together with talcum as the carrier substance. The monograph D. IT07.10.4 referred to in the bibliography of the IKS Monthly of 12/1994 describes mustard seed and camomile flowers as pharmaceutically effective substances in the cutaneous treatment of arthritis and rheumatic disorders. Then there are a number of sulfur-containing preparations, indicated for "rheumatism", in the form of bath oils and additives with names such as "Soufrol", "Sulfur-Oil-Bath" and "Leukona Sulfomoor-Bath".
-2 This invention is aimed at introducing another pharmaceutical preparation with good and/or improved properties for the treatment of rheumatic syndromes. The active agents contained in the pharmaceutical preparation according to this invention for the treatment of rheumatic syndromes and especially rheumatism, arthritis, sciatica and/or gout include at least sulfur, mustard seed and a cupric salt. The characterizing features of other preferred pharmaceutical compositions are specified in the subclaims. The invention also covers a cutaneous form of administration, for the treatment of rheumatic syndromes, of a pharmaceutical preparation per this invention. The cutaneous form of administration preferably employs a fine-particle foot powder specially prepared for application on the sole of the foot. The preferred fine foot powder is sprinkled into shoes, socks, stockings or liners whereupon the active ingredients are absorbed into the blood stream through the sole of the foot. This is a unique form of applying a rheumatism antidote and constitutes a particular aspect directly associated with the special combination of the individual active ingredients as proposed by this invention. The functional mechanism is based on the fact that, as the substance makes contact with live and keratinous tissue (that being the sole of the foot), a number of chemical transformations take place, aided by the effect of natural aspiration, even natural perspiration, leading to corresponding reactions in two -3 ways, i.e. by way of both the blood stream and the nerve tissue. As an obvious prerequisite, the active agents must be adequately resorbed by the skin, which is assured by the particular combination of active ingredients per this invention. By virtue of the above-mentioned transdermal absorption the organism will only take up exactly the amount of active substances that it needs. Key components of the compounds introduced by this invention are such active ingredients, present in trace amounts only, as cupric salt which preferably consists of copper sulfate, and potassium iodate, to both of which a certain catalytic effect is attributed. Correspondingly, these two substances, in conjunction with talc as the carrier substance, form a so-called "catalytic powder" which is added in minuscule amounts to the other active agents including in particular sulfur and mustard seed. The process of producing the pharmaceutical preparation begins with a first step in which talc is mixed with sulfur as the active agent plus, as an option, camphor and camomile flowers. For the blending operation the active ingredients are prepowderized and, of course, the talc, or talcum, constituting the carrier substance, is pulverulent on its part. As the second step of the process, a minuscule amount of the above-mentioned so-called "catalytic powder" is added to the mixture. The catalytic powder again consists of talc as well as mustard seed, the cupric salt preferably in the form of copper sulfate, and, as an option, potassium iodate.
-4 The advantage of adding potassium iodate derives in particular from the fact that it stabilizes the pharmaceutical preparation for use in hot or tropical regions. The talcum carrier substance is known to be less than absolutely stable or suitable for use in tropical or hot zones, which makes the addition of potassium iodate necessary or advisable. The following explains this invention in more detail with the aid of the production-process examples given below and with reference to a sample composition. As mentioned above, the production follows a bipartite process, i.e. the pharmaceutical preparation according to this invention is produced in two steps, dividing the composition into two parts. Part 1: Sulfur: Approx. 30 - 50 % by weight, preferably 30 - 40 % by weight; Camomile: 0 - 10 %, preferably 5 - 10 %; Camphor: 0 - 25 %, preferably 15 - 25 %; Talcum (balance): 20-65 %. Total, Part 1: 85-95% Part 2: Mustard seed: 0.5 - 2.5 %, preferably 1 - 1.5 %; Copper sulfate: 0.05 - 0.3 %, preferably 0.1 - 0.15 %; Potassium iodate: 0 - 0.15 %, preferably 0.05 - 0.1 % Talcum: 3-13% Total, Part 2: 5- 15% -5 The quantities expressed in percent by weight relate to the total weight of the preparation composed of Part 1 and Part 2. For producing the preparation, the first step is to mix Part 1 for which purpose the individual components are ground into ultrafine powder and screened, then blended with talc in a mixer, for instance a so-called 4-way mixer, for about 15 minutes. Part 2 is produced by first grinding copper sulfate and, if applicable, potassium iodate in a mortar using a pestle until a homogeneous powder is obtained. These components are then sifted, together with talc and mustard seed, for instance through a 0.5mm-mesh screen and are then added to and blended with the mixture of Part 1. This can again be performed in a 4-way mixer, in this case for about 20 minutes. Of course, the above quantities are indicated as examples only, subject to variation and modification depending on the application i.e. form of administration and on the ailment to be treated. Likewise, the mixtures can naturally be produced by methods deviating from that described above. It is important, however, that especially when a foot powder is produced, the different components making up the foot powder be thoroughly mixed kU -6 so as to result in a fine powder mixture. It is also possible to administer the preparation in the form of a cream, paste or the like, containing the pharmaceutical preparation for instance as an ultrafine powder together with carrier substances and other additives. Apart from the indications first above mentioned, the pharmaceutical preparations according to this invention have also been found to be suitable for application in the case of the following disorders or ailments: Sciatia, muscular rheumatism, arthritis, phlebitis (inflammation of a vein), excessively high or low blood pressure, paralysis deformans, paralysis post myelitis, poliomyelitis, paralysis cerebralis, paralysis post nephritis vel uraemia, paralysis postlaesion cause alicuia mechanica, eczema, and x-ray burns.

Claims (12)

1. Pharmaceutical preparation for treating rheumatic syndromes, especially rheumatism, arthritis, sciatica and/or gout, characterized in that it contains at least the following active agents: Sulfur, mustard seed as well as a cupric salt.
2. Pharmaceutical preparation especially as per claim 1, characterized in that the cupric salt employed is copper sulfate.
3. Pharmaceutical preparation especially as per claim 1 or 2, additionally containing camomile and preferably camomile flowers.
4. Pharmaceutical preparation especially as per one of the claims 1 to 3, containing talc as its carrier substance.
5. Pharmaceutical preparation especially as per one of the claims 1 to 4, additionally containing camphor.
6. Pharmaceutical preparation especially as per one of the claims 1 to 5, additionally containing potassium iodate.
7. Pharmaceutical preparation especially as per one of the claims 1 to 5, chararized in that the preparation is produced in powder form.
8. Pharmaceutical preparation especially as per one of the claims 1 to 7, characterized by the following volume concentrations of the various components: -8 Sulfur: 30 - 50 % by weight, preferably 30 - 40 % by weight; Camomile: 0 - 10 % by weight, preferably 5 - 10 % by weight; Camphor: 0 - 25 % by weight, preferably 15 - 25 % by weight; Mustard seed: 0.5 - 2.5 % by weight, preferably 1 - 1.5 % by weight Copper sulfate: 0.05 - 0.3 % by weight, preferably 0.1 - 0.15 % by weight; Potassium iodate: 0 - 0.15 % by weight, preferably 0.05 - 0.1 % by weight; Talc making up the remainder up to 100 % by weight.
9. Cutaneous form of administration employing a pharmaceutical preparation per one of the claims 1 to 8.
10. Cutaneous administration especially as per claim 9, characterized in that it is in the form of a foot powder suitable for application on the sole of the foot.
11. Process for producing a pharmaceutical preparation as in one of the claims 1 to 9, characterized in that, in a first step, talc and sulfur are mixed in powder form, followed by a second step in which a small amount of a so-called "catalytic powder" is added, said catalytic powder being a pulverulent mixture composed of talc, mustard seed and a cupric salt, especially copper sulfate.
12. Process especially as in claim 11, characterized in that in the first phase, camphor and/or camomile in the form of camomile flowers are optionally added and that in the second phase potassium iodate is further added to the "catalytic powder".
AU19616/00A 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt Ceased AU747416B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100923A EP0983766A1 (en) 1999-01-20 1999-01-20 A pharmaceutical composition for the treatment of rheumatoid disorders comprising sulphur, mustard seeds and a copper salt
EP99100923 1999-01-20
PCT/CH2000/000027 WO2000043021A1 (en) 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt

Publications (2)

Publication Number Publication Date
AU1961600A true AU1961600A (en) 2000-08-07
AU747416B2 AU747416B2 (en) 2002-05-16

Family

ID=8237372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19616/00A Ceased AU747416B2 (en) 1999-01-20 2000-01-19 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt

Country Status (10)

Country Link
EP (1) EP0983766A1 (en)
JP (1) JP2002535280A (en)
KR (1) KR20010113657A (en)
CN (1) CN1337882A (en)
AU (1) AU747416B2 (en)
BR (1) BR0007641A (en)
CA (1) CA2358474A1 (en)
IL (1) IL144439A0 (en)
NO (1) NO20013555L (en)
WO (1) WO2000043021A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007257286B2 (en) 2006-06-02 2013-02-21 Natural Ma Inc. Use of Micron-sized sulphur for the Prevention and Treatment of Pathogenic Disorders in Humans and Animals
CN104225112B (en) * 2013-06-13 2017-12-22 陈卫衡 A kind of Chinese medicine composition for treating Osteoarthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8128911U1 (en) * 1981-10-02 1982-06-16 Energy-Pak Europe Ltd., 9490 Vaduz Magnetic plaster
CH660971A5 (en) * 1983-07-07 1987-06-30 Schwab F A & Co Therapeutic composition
DE3433076A1 (en) * 1984-09-08 1986-03-20 Alfred Dipl.-Biochem. 7400 Tübingen Gärtner Process for the isolation and use of copper metallothioneins for antirheumatic therapy
CN1032622C (en) * 1993-01-19 1996-08-28 王来运 Medical liquid for relaxing tendons and joints
CN1099970A (en) * 1993-09-11 1995-03-15 宋建祥 Health clothing and articles with Chinese medicines and producing method thereof
CN1130074A (en) * 1995-03-01 1996-09-04 李凤欣 External application medicine for chronic rheumatic hyperosteogeny
GB2315674B (en) * 1996-08-01 2000-06-21 Richard John Cleeve Mammalian foodstuff
CN1191729A (en) * 1997-02-20 1998-09-02 李国荣 Pain paster
CN1164410A (en) * 1997-04-22 1997-11-12 高贵 External use preparation for curing phlebitis
CN1049353C (en) * 1997-07-30 2000-02-16 张巨文 Chinese medicinal preparation for curing rheumatism and rheumatoid disease and its prepn. method
CN1057001C (en) * 1997-09-10 2000-10-04 沈春楼 Chinese medicine capsule for rheumatoid disease

Also Published As

Publication number Publication date
EP0983766A1 (en) 2000-03-08
NO20013555L (en) 2001-09-10
NO20013555D0 (en) 2001-07-18
IL144439A0 (en) 2002-05-23
KR20010113657A (en) 2001-12-28
BR0007641A (en) 2001-10-16
WO2000043021A1 (en) 2000-07-27
CA2358474A1 (en) 2000-07-27
JP2002535280A (en) 2002-10-22
CN1337882A (en) 2002-02-27
AU747416B2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE68928920T2 (en) FATTY ACID MEDICINE CONJUGATE FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS THROUGH THE BLOOD BRAIN BARRIER
KR100329249B1 (en) Nasal administration composition
KR19990083970A (en) Phamaceutical compositions for treating rheumatism and method for production thereof
DE2543350C2 (en) Preparations for the manufacture of ↑ 9 ↑ ↑ 9 ↑ ↑ m ↑ Technetium radio diagnostics
CN101167730B (en) Compound betamethasone suspension injection
KR19990082461A (en) How to treat drugs and organisms with drugs
CN101827807A (en) The method of the amorphous and amorphous crystalline glucose acid calcium salt of processing machinery activatory
EP0108882B1 (en) Compressed pills with retarded liberation of active material, and process for their preparation
AU1961600A (en) Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt
DE69103624T2 (en) PHARMACEUTICAL PREPARATIONS CONTAINING IPRIFLAVONE, METHOD FOR THE PRODUCTION AND THERAPEUTIC USE.
EP0198172B1 (en) Pharmaceutical preparation
CN102302511A (en) Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction
DE3874320T2 (en) TABLET TO TREAT PROGESTERONE DEFICIENCY.
DE69624935T2 (en) ORAL GEL CAPSULE FORMULATION OF 1,2,4-BENZOTRIAZINE OXIDES
KR20050089466A (en) Pharmaceutical compositions for treating rheumatism and method for production thereof
RU2203040C1 (en) Medicinal composition for physical therapy and cosmetology
RU2109508C1 (en) Paste for dermal sickness treatment
WO1996033707A1 (en) Topical preparation for promoting muscular development
KR100347883B1 (en) New pharmaceutical composition of gel preparation containing local anaesthetic agents
DE69001540T2 (en) MEDICINAL PRODUCTS FOR RECTAL ADMINISTRATION OF CALCITONIN.
KR19980021968A (en) Bath additive based on ocher soil
JP3256369B2 (en) Skin cosmetics
RU2180581C1 (en) Composition for treatment of inflammatory and degenerative diseases of locomotor apparatus
KR900017593A (en) Imidazodiazepine for the treatment of neurological symptoms
CA1282337C (en) Method for treating drug addiction

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 44, PAGE(S) 7916-7918 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 19616/00

FGA Letters patent sealed or granted (standard patent)